In studies conducted at Brigham and Women’s Hospital of the Harvard University School of Medicine, AZD-103 was shown to be highly effective at neutralizing the short term effects of amyloid beta oligomers on synaptic function in hippocampal slices from mice.
Based on these encouraging findings, Transition believes AZD-103 continues to demonstrate the efficacy and safety profile necessary to be considered as a leading drug candidate for the treatment of Alzheimer’s disease patients.
The company’s lead compound is part of an emerging class of disease-modifying agents that have the potential to both reduce disease progression and improve symptoms such as cognitive function. AZD-103 breaks down neurotoxic fibrils, allowing amyloid peptides to clear from the brain rather than accumulate and aggregate to form amyloid plaques, a hallmark pathology of Alzheimer’s disease.
In addition, Transition says AZD-103 is well positioned as an Alzheimer’s therapy as it is taken orally, crosses the blood brain barrier and has an excellent safety profile.